Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer…
Search
Tag: Nasdaq:ALLR